EPZICOM

LOE Approaching

abacavir sulfate; lamivudine

NDAORALTABLET
Approved
Aug 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5

Mechanism of Action

Mechanism of Action: Abacavir is a carbocyclic synthetic nucleoside analogue. Abacavir is converted by cellular enzymes to the active metabolite, carbovir triphosphate (CBV-TP), an analogue of deoxyguanosine-5′-triphosphate (dGTP). CBV-TP inhibits the activity of HIV-1 reverse transcriptase (RT)…

Indications (1)

Clinical Trials (5)

NCT02626923N/ACompleted

Study of Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in ART-Naive & First Switch Patients

Started Jul 2012
51 enrolled
Drug-induced Hypotension
NCT01102972Phase 4Completed

A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)

Started Apr 2010
297 enrolled
Infection, Human Immunodeficiency Virus
NCT00724711Phase 4Completed

Safety and Efficacy Study of Switching From Epzicom to Truvada

Started Jul 2008
312 enrolled
HIV Infection
NCT00740064Phase 4Unknown

Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects

Started May 2008
30 enrolled
HIV Infections
NCT00337922Phase 4Completed

Pharmacokinetic Study Of EPZICOM Tablet

Started Jul 2006
8 enrolled
HIV Infection